Blum Michael Lee 4
4 · Homology Medicines, Inc. · Filed Jan 4, 2023
Insider Transaction Report
Form 4
Blum Michael Lee
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-01-01+2,640→ 11,042 total - Exercise/Conversion
Common Stock
2023-01-01+4,950→ 15,992 total - Exercise/Conversion
Restricted Stock Units
2023-01-01−2,640→ 2,720 total→ Common Stock (2,640 underlying) - Exercise/Conversion
Restricted Stock Units
2023-01-01−4,950→ 10,050 total→ Common Stock (4,950 underlying)
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
- [F2]Includes 630 shares acquired under Issuer's Employee Stock Purchase Plan on February 28, 2022 and 992 shares acquired under Issuer's Employee Stock Purchase Plan on August 31, 2022.
- [F3]The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one half of the RSUs on each of January 1, 2023 and January 1, 2024. The RSUs do not have an expiration date.
- [F4]The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.